

Professor Kyriakos E. Kypreos received his Ph.D. in Biochemistry in 1998 from [Boston University Medical School Division of Graduate Medical Sciences](#) (Boston, MA. U.S.A). Following his graduation, Prof. Kypreos did his post-doctoral training at the Whitaker Cardiovascular Institute at Boston University Medical Center in the U.S.A (1998-2002) and at Leiden University Medical Center, Department of Human Genetics (2002-2004) in the Netherlands. In 2004 he returned to the USA where he became Instructor and in 2006 Research Assistant Professor in Medicine at [Boston University School of Medicine](#). From 2001 to 2007 Prof. Kypreos served on the scientific advisory board of [KOS Pharmaceuticals](#) during which time he was introduced to the world of Pharmacology. In 2008, he was appointed as Associate Professor of Pharmacology at [The University of Patras School of Health Sciences, Department of Medicine](#), in Greece, where in December 2013, he was promoted to the rank of full [Professor of Pharmacology](#). Since September 2014, he is the Chairman of the Pharmacology laboratory of the Department of Medicine at the University of Patras School of Health Sciences. At this capacity, he established the service unit “[Center for Clinical Pharmacology and Toxicology](#)” of the laboratory aiming at facilitating precision medicine decisions. In addition to his main appointment, since September 2019 he also holds a secondary academic appointment as Adjunct Professor of Pharmacology and Metabolic Disorders at the [European University Cyprus, School of Sciences, Department of Life Sciences](#).

Prof. Kypreos' research interests focus on the pharmacology of metabolic syndrome. In particular his team research the mechanisms underlying the development of the pathological conditions associated with metabolic syndrome with emphasis placed on the lipoprotein transport system. Ultimate goal of their studies is the identification of novel pharmacological targets and the development of lead compounds for the treatment of these conditions. Prof. Kypreos' previous research works have been featured in high profile international media including [ASBMBToday](#).

Prof. Kypreos has been an EMBO Fellow, a Marie-Curie Fellow , and the winner of “[Irvine H. Page](#)” [Atherosclerosis Research Award](#), offered by the ATVB council of the [American Heart Association](#). His research activities have been funded by competitive research grants from the [General Secretariat for Research and Technology](#), the [Hellenic Foundation for Research and Innovation](#), the [Hellenic State Scholarship Foundation](#), the European Community and the industry.

Prof. Kypreos is member of the editorial board of the [American Journal of Physiology-Endocrinology and Metabolism](#), the [Journal of Biomedical Research](#), the journal [Androgens](#) and the Journal [Nutrients](#). As of Dec 1 2018, Prof. Kypreos is an elected member of the Executive Committee of the Hellenic Atherosclerosis Society (HAS), an affiliate of the [European Atherosclerosis Society \(EAS\)](#).

Since 2016, Prof. Kypreos is the vice chairman of the National Pharmacovigilance Committee (EFAR), the committee responsible for the safety of medicines and vaccines for human use. Prof. Kypreos also served in the past as member of the Health Technology Assessment (HTA) committee (EAAΦAX) of the Hellenic Ministry of Health, the committee responsible for evaluating all new drug applications for being

reimbursed by the public health system.

In addition, Prof. Kypreos has extensive teaching duties. Currently, he co-coordinates and teaches various Pharmacology courses for medical and graduate students at the University of Patras Medical School and other Institutions in Greece and abroad.

According to [Expertscape](#), a worldwide registry of experts, Prof. Kypreos' expertise on:

**Lipoproteins** ranks in the top 0.23% worldwide among 177,496 published authors from 2010 to 2021. <http://expertscape.com/.../hyperlipidem.../Kypreos%2C+Kyriakos+E>

**Apolipoproteins E (APOE)**, ranks in the top 0.87% worldwide among 45,799 published authors from 2010 to 2021.

<http://expertscape.com/au/apolipoproteins+e/Kypreos%2C+Kyriakos+E>

**High Density Lipoprotein (HDL)** ranks in the top 0.22% worldwide among 67,266 published authors from 2010 to 2021.

<http://expertscape.com/au/lipoproteins%2C+hdl/Kypreos%2C+K+E>

**Apolipoprotein A1 (APOA1)** ranks in the top 0.68% worldwide among 14,281 published authors from 2010 to 2021.

<http://expertscape.com/au/apolipoprotein+a-i/Kypreos%2C+K+E>

For Prof. Kypreos' most current publication record please refer to [PubMed](#). For updated statistics on his published work please visit [google scholar](#) or [scopus](#). Prof. Kypreos' orchid profile may be found at [orcid.org/0000-0001-6784-2710](http://orcid.org/0000-0001-6784-2710) and his linkedin profile at <http://www.linkedin.com/in/kyriakosekypreos>